Compare DSGN & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSGN | IBEX |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.9M | 489.1M |
| IPO Year | 2021 | 2017 |
| Metric | DSGN | IBEX |
|---|---|---|
| Price | $10.31 | $27.71 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | $15.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 234.9K | 168.1K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.05 | ★ 28.26 |
| EPS | N/A | ★ 1.65 |
| Revenue | N/A | ★ $558,273,000.00 |
| Revenue This Year | N/A | $13.14 |
| Revenue Next Year | N/A | $5.67 |
| P/E Ratio | ★ N/A | $16.77 |
| Revenue Growth | N/A | ★ 9.77 |
| 52 Week Low | $2.62 | $21.64 |
| 52 Week High | $10.97 | $42.99 |
| Indicator | DSGN | IBEX |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 21.36 |
| Support Level | $9.54 | N/A |
| Resistance Level | N/A | $30.62 |
| Average True Range (ATR) | 0.52 | 2.16 |
| MACD | -0.04 | -0.46 |
| Stochastic Oscillator | 65.66 | 0.53 |
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.